PNOĒWinter 2019Active☆Watch⊞Compare

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Enabling health professionals to prescribe clinical-grade wellness…

PNOĒ enables health professionals to provide science-backed bio-optimization through breath analysis. For 100+ years, breath analysis (AKA metabolic testing, VO2max) has been the gold standard in anti-aging quantification, nutrition prescription, and evaluation of most critical systems, including the heart, lungs, cells, and nervous system. Until recently, it was only available in sophisticated clinics and regarded as the most valuable but underutilized assessment in medicine. PNOĒ changed that through the first easy-to-use clinical-grade breath analysis device, proprietary software package, and dedicated metabolic expert support. Through a non-invasive 10 min breath test, PNOĒ analyzes the human breath and prescribes a personalized nutrition, exercise, breathwork, and bio-optimization (i.e., red light therapy, hyperbaric chamber, IV therapy, etc.) program based on one’s biological limitations. 3,000+ health professionals trust PNOĒ because it personalizes the clients’ journey through their clinics, builds retention by quantifying progress, and enables the upsell of personalized nutrition and breathwork. All this without any effort, time commitment, or upfront cost. PNOĒ has been independently validated by Georgetown University, VA in Maryland, and Rutgers University and is trusted by leading institutions including Cenegenics, Dais Cove, MIT, UCLA, Pan Pacific, CLMBR, UCS, OURA, TONAL, Spartan Racing, and Paris Saint Germain.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

PNOĒ is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where PNOĒ sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at PNOĒ, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.